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Oxygen free radicals are mediators of tissue injury and catalase is an enzyme which is involved in 
limiting this process. We examined peripheral blood catalase activity (PBCA) to assess its value as a 
marker in detecting tissue injury related to renal allograft rejection. Thirty-one consecutive recipients 
of kidney (n = 29) or simultaneous kidney/pancreas (n = 2) transplants and 10 normal volunteers were 
studied. Catalase activity, measured by the disk-flotation method, was expressed as Sigma units 
X 10e3/ml (SU/ml) of whole blood. Normal PBCA was determined to be greater than 76 SU/ml. 
Twenty-nine episodes of renal allograft rejection (diagnosed by clinical criteria f biopsy [79%]) were 
observed in 26 patients. PBCA (mean + SEM) was found to be low (64 t 1 SU/ml) in 28/29 episodes 
(X2 = 46.3, P < O.OOl), and the decrease (at least two consecutive daily catalase values < 76 SU/ml) 
occurred 2 days prior to the clinical/biopsy diagnosis of rejection in 26/28 episodes. The sensitivity of 
PBCA as a discriminant of rejection was 97%, specificity was 96%, and test accuracy was 96%. PBCA 
less than 50 SU/ml on two or more occasions occurred in five cases and transplant nephrectomy was 
required in four of these because of uncontrollable rejection. Nine episodes of cyclosporine nephrotox- 
icity occurred in 7 patients and none of these episodes was associated with a decreased PBCA. Our data 
suggest that decreased PBCA is a sensitive and specific indicator of renal allograft rejection. PBCA 
remains normal during episodes of cyclosporine nephrotoxicity and therefore provides a rapid and 
inexpensive discriminant from allograft rejection. 0 1988 Academic Press, Inc. 
INTRODUCTION 
The molecular mechanisms responsible 
for allograft destruction are not well defined. 
One possible mechanism involves the partic- 
ipation of cells, such as polymorphonuclear 
leukocytes, macrophages, and monocytes, 
which are able to undergo a “respiratory 
burst” [ 1,2] and subsequently generate toxic 
oxygen free radicals [ 1, 5, 61. These sub- 
stances result in peroxidative damage to the 
lipid bilayer of cell membranes and ulti- 
mately cause cell death. 
Normal tissues contain enough endoge- 
nous scavengers to protect against oxygen 
free radical damage. Such defense systems, 
however, may be affected by the ongoing re- 
jection and destruction of a transplanted 
graft [7]. In this regard, the activity of the 
primary antioxidant defense enzyme super- 
’ Supported by the McLauglin Foundation of Canada. 
oxide dismutase has been found to be de- 
creased in rejecting rat cardiac allografts [7]. 
Catalase, the first enzyme ever described 
181, is an antioxidant enzyme whose primary 
function is to metabolize hydrogen peroxide 
(H202) to HZ0 and O2 [8,9]. Catalase activity 
in urine and blood has been studied in a vari- 
ety of disease states [8, 10, Ill, including 
acute and chronic renal failure [ 121, and has 
always been found to be elevated. The hyper- 
catalasemia of uremia is reduced by dialysis 
and in the early post-transplant period [ 121. 
The purpose of our investigation was to 
study peripheral blood catalase activity to 
assess its value as a marker of renal allograft 
rejection. 
MATERIALS AND METHODS 
Patients 
A study of consecutive cadaver-donor (n 
= 2 1) and living-related-donor (n = 10) renal 
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transplant recipients (13 females; 18 males) 
with a mean age of 33 years (range 9-57 
years) was carried out. Twenty-eight patients 
received a primary renal graft. One patient 
received a second renal allograft and two un- 
derwent simultaneous kidney/pancreas 
transplantation. Renal recipients were im- 
munosuppressed with prednisone (1.5 mg/kg 
in preop and then tapered to 0.25 mg/kg po 
over 4 weeks) and cyclosporine (5 mg/kg iv 
and then 16 mg/kg po to maintain a blood 
level of 150-250 rig/ml by HPLC). One re- 
cipient of an HLA-identical living-related 
kidney received prednisone and azathioprine 
(3 mgjkg po preoperatively and 3 mg/kg 
pa/iv daily up to a maximum of 200 mg/ 
day). Recipients of combined renal/pancreas 
transplants received quadruple immunother- 
apy with prednisone and cyclosporine as for 
renal transplants, azathioprine (1.5-2.5 
mg/kg pa/iv daily up to a maximum of 200 
mg/day), and Minnesota antilymphoblast 
globulin (20 mg/kg iv for 10 days). All pa- 
tients were studied until discharge from hos- 
pital and then weekly in the outpatient 
clinic. Median time of follow-up was 6 
weeks. 
Diagnosis of Rejection 
The diagnosis of graft rejection was estab- 
lished by an independent observer on the 
basis of at least three of the following clinical 
criteria as suggested by McWhinnie et al. [4]. 
( 1) Graft tenderness + swelling. 
(2) Fever (in the absence of infection). 
(3) Oliguria (in the absence of urinary ob- 
struction) or a decreasing urine output of ap- 
proximately lO%/day on the 2 preceding 
days. 
(4) A rising creatinine of approximately 
lO%/day on the 2 preceding days. 
(5) Response to a series of methylpredni- 
solone pulses. 
In addition, confirmatory percutaneous 
biopsies were obtained in 79% of rejection 
episodes. Twenty-nine rejection episodes 
were diagnosed in 26 patients. 
Diagnosis of Cyclosporine Nephrotoxicity 
Cyclosporine nephrotoxicity was diag- 
nosed if abnormal renal function improved 
following a reduction in cyclosporine dosage. 
In each instance, the cyclosporine blood level 
was greater than 250 rig/ml and there was no 
clinical/biopsy evidence of rejection, ob- 
struction, or infection. 
Determination of Peripheral Whole Blood 
Catalase (PBCA) 
PBCA was analyzed using the disk-flota- 
tion technique described by Gagnon et al. 
[ 131 and Charbonneau et al. [ 141 which takes 
advantage of the specific ability of catalase to 
cleave HZ02 into HI0 and OZ. As the reac- 
tion proceeds, bubbles of oxygen are liber- 
ated and cause the disk to float to the surface. 
Disk-flotation time (in seconds) is inversely 
related to catalase activity. 
Procedure 
(1) Heparinized blood samples (5-10 ml) 
were collected daily and refrigerated at 10°C. 
Samples were brought to room temperature 
prior to PBCA determination. 
(2) Blood samples were diluted 1: 1000 
with 0.9% saline solution in a glass tube. 
(3) Using fine forceps, a filter paper disk 
(Whatman, quality No. 1) of uniform diame- 
ter (7 mm, standardized using a hole punch) 
was placed for 3 set into the glass tube con- 
taining the solution of diluted blood. 
(4) The saturated disk was gently trans- 
ferred to a second glass tube containing 8 ml 
of 3% H202 (Medikay). When the disk settled 
at the bottom, a digital timer was started. 
When the disk reached the top of the column 
of hydrogen peroxide, the timer was stopped. 
(5) Samples were run in triplicate and the 
results were averaged. Interassay and in- 
traassay variabilities were less than 10%. 
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Development of a Standard Curve of TABLE I 
Cataiase Activity PERIPHERAL BLOOD CATALASE ACTIVITY IN RENAL 
ALLOGRAFT RECIPIENTS 
Catalase was purchased from Sigma 
Chemical Co., St. Louis, Missouri (Catalog 
No. ClOO) with a specific activity of 44,200 
Sigma units (SU) per milligram. One SU of 
catalase activity is defined as that amount of 
enzyme which decompose 1 .O PM of Hz02 in 
1 min at pH 7.0 at 25°C. 
Disk-flotation times were determined for 
catalase samples of known activity. A loga- 
rithmic regression was performed by a least- 
squares method using a commercial software 
package and microcomputer (Fig. 1). The 
correlation coefficient for the regression 
equation was 0.96. Results were expressed as 








Note. Sensitivity = 97%, specificity = 96%, accuracy 
= 96%. 
‘No rejection episodes, n = 6; following recovery 
from a rejection episode, n = 19. 
an actual decrease in the amount of enzyme, 
blood from a patient with documented rejec- 
tion and low PBCA was diluted 1: 1000 with 
0.9 saline as per our protocol. Aliquots were 
then mixed, in dilutions of 1:4, 1:2, and 1: 1 
(rejecting:normal), with samples of saline-di- 
luted blood taken from a normal volunteer. 
PBCA was then determined on the mixed 
specimen. 
Establishment of Normal PBCA Using the 
Disk-Flotation Method 
Samples were obtained from 10 healthy 
age-matched volunteers for determination of 
PBCA. PBCA (mean 5~ SD) for these individ- 
uals was 96 + 10 SU/ml. The 95% confi- 
dence level for the lower limit of PBCA in 
healthy individuals was 76 SU/ml. PBCA 
less than 76/SU/ml on 2 consecutive days 
was considered to be abnormal. 
Mixing Studies 
To determine whether a low PBCA in pa- 
tients undergoing rejection was due to the 
presence of a blocking factor as opposed to 
100 200 
Catalase (S.U. /ml) 
300 
FIG. 1. Standard curve for peripheral blood catalase 
activity by disk-flotation method. Logarithmic regres- 
sion by least-squares method, Y = (1.997) ( 104) 
(K’.59’7), R = 0.96. 




Comparisons of frequency were per- 
formed by x2 analysis. Comparisons of 
means were performed by the nonparametric 
Wilcoxon rank sum test or signed rank test, 
where appropriate. P < 0.01 was considered 
significant. 
RESULTS 
Allografi rejection was associated with sig- 
nificantly decreased PBCA. As shown in 
Table 1, decreased PBCA was observed in 28 
of 29 rejection episodes (sensitivity = 97%). 
Conversely, normal PBCA was seen in five of 
six rejection-free patients and in all patients 
(n = 19) who recovered from a rejection epi- 
sode (specificity = 96%). PBCA results, 
therefore, had an overall accuracy of 96% in 
diagnosing the presence or absence of rejec- 
tion (x2 = 46.3; P < 0.001). 
One false positive result occurred in a pe- 
diatric recipient who has never had a clinical 
or biopsy diagnosis of rejection. This patient 
has had no infections or other complications 
during the 8 months post-transplant. The 
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only false negative occurred in a recipient of 
an HLA-identical living-related kidney. On 
the fifth post-transplant day, the serum creat- 
inine level rose from 1.4 to 2.5 mg/dl and 
low grade fever, hypertension, decreased 
urine output, and slight graft tenderness were 
noted. Whole blood cyclosporine trough 
levels remained in the therapeutic range dur- 
ing this interval and a response to intrave- 
nous methylprednisolone was noted over the 
following 3 days. 
Aside from the single example of a false 
negative, decreased PBCA was noted at least 
48 hr prior to the clinical and/or biopsy 
diagnosis of allograft rejection in every case. 
In 26 or 28 rejection episodes, decreased 
PBCA occurred 2 days prior to the diagnosis 
of rejection and catalase criteria were met 5 
and 7 days prior to the diagnosis in the re- 
maining two cases. 
Mean PBCA 48 hr prior to the clinical dec- 
laration of rejection was 64 t- 1 SU/ml. 
PBCA in (n = 22) recipients who experi- 
enced allograft rejection within the initial 10 
days post-transplant was significantly less 
than in recipients (n = 11) who were rejec- 
tion-free during this interval (75 f 0.3 vs 82 
it 1 SU/ml; P = 0.013). A rise in PBCA to 
well within the normal range was seen during 
the fourth through sixth days in all patients 
not experiencing a rejection episode. 
Changes in PBCA paralleled, in general, 
the clinical response to antirejection treat- 
ment. A gradual rise in PBCA toward nor- 
mal was seen in most patients coincident 
with a salutary response to increased immu- 
nosuppression. Patients who had a rejection 
episode associated with low PBCA and who 
were successfully treated had a PBCA on dis- 
charge of 83 + 2 SU/ml. In six cases of rejec- 
tion, PBCA continued to fall for at least 7 
days. Further increases in immunosuppres- 
sive therapy with continued intravenous ste- 
roid pulses or antilymphoblast globulin were 
required in four of the six to control the re- 
jection episodes. The other two patients had 
eventual restoration of normal PBCA at 14 
and 24 days, respectively, after antirejection 
therapy. Patients who did not experience a 
rejection episode and whose PBCA remained 
normal during the course of hospitalization 
had a mean PBCA at discharge of 81 -t 4 
SU/ml. 
Transplant nephrectomy was performed 
for severe rejection in six individuals who 
had low PBCA. In four of these cases, PBCA 
was less than 50 SU/ml on two or more oc- 
casions. Overall, there were five patients in 
the study group with PBCA less than 50 
SU/ml on two or more occasions, of whom 
four required transplant nephrectomy for 
uncontrollable rejection. 
Nine episodes of cyclosporine nephrotox- 
icity were encountered in seven patients. A 
high cyclosporine blood trough level was 
noted in each case. There were no clinical 
signs consistent with rejection aside from 
elevated serum creatinine levels. The sine 
qua non of nephrotoxicity was a return of 
serum creatinine levels toward normal fol- 
lowing reduction of the cyclosporine dose. In 
one case, a biopsy further substantiated the 
diagnosis of nephrotoxicity. Measurements 
of PBCA during these nine episodes of cy- 
closporine nephrotoxicity were normal in 
every case. 
DISCUSSION 
Catalase, the first enzyme to be identified, 
was described by Thernard in 18 18 [8]. 
While the highest concentrations of catalase 
are in liver, erythrocytes, kidney, heart, mus- 
cle, spleen, lung, pancreas, skeletal muscle, 
and brain, significant catalase activity is also 
found in white blood cells [8]. The primary 
function of this ubiquitous enzyme is the 
metabolism of hydrogen peroxide to water 
and oxygen [8, 91. 
In the clinical setting, catalase activity has 
been determined in urine [ 14-161, serum [8, 
lo], erythrocytes [ 121, and whole blood [ 171. 
In each instance, the method utilized was 
different, as were the units for expressing en- 
zyme activity. The disk-flotation method for 
the measurement of catalase activity was 
proposed by Gagnon and colleagues in 1959 
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[ 131 and has been shown to be a simple, 
rapid, and accurate assay [ 14, 15, 181. 
We measured peripheral blood catalase ac- 
tivity (PBCA) in 31 renal transplant recipi- 
ents and in 10 normal volunteers utilizing 
the disk-flotation method. PBCA was de- 
creased in 96% of rejection episodes. Fur- 
thermore, very low levels of PBCA (less than 
50 SU/ml on two or more occasions) were 
indicative of a more severe allograft rejection 
reaction which required a transplant 
nephrectomy in four of five individuals. Suc- 
cessful treatment of a rejection episode was 
associated with a normalization of PBCA. Of 
those patients with persistently low PBCA 
following initial antirejection therapy with 
methylprednisolone, two-thirds required ad- 
ditional steroid pulses and/or antilympho- 
blast globulin. 
Allograft rejection may be precipitated by 
subtherapeutic levels of cyclosporine. We ex- 
amined PBCA and cyclosporine blood levels 
when rejection was diagnosed but found no 
significant correlation. Of interest were the 
nine episodes of cyclosporine nephrotoxicity 
which were identified. On each occasion, the 
patient presented with a cyclosporine level 
greater than 250 rig/ml, a rising serum creati- 
nine in the absence of other objective criteria 
of allograft rejection, and a PBCA that was 
normal. A decrease in the cyclosporine dos- 
age was associated with a fall in serum creati- 
nine in each case. 
The pathogenesis of allograft rejection is 
incompletely understood. Hayry et al. [3] 
have described the process of rejection as 
consisting of four overlapping components: 
(i) induction of rejection, (ii) the immune 
response toward the graft, (iii) the inflamma- 
tory response and the regulation of inflam- 
mation by the immune response, and (iv) the 
effector mechanisms in situ. 
Recently, the cellular nature of the inflam- 
matory infiltrate in the rejecting renal allo- 
graft has become the subject of considerable 
interest. In drug-unmodified rejection, 
monocytes are detected in a kidney allograft 
as early as the first day of transplantation [I]. 
With ongoing rejection, a rapid maturation 
of blood-borne monocytes into tissue macro- 
phages occurs and progressive destruction of 
the graft ensues. In severe rejection substan- 
tial numbers of polymorphonuclear leuko- 
cytes also infiltrate the graft [3]. In this set- 
ting, tissue injury may be mediated by the 
generation of phagocyte-derived oxygen free 
radicals, the so-called respiratory burst [ 1,2]. 
Superoxide anion and hydroxyl radicals 
thereby produced are toxic to biomolecules 
[5,6] and can lead to cellular injury through 
lipid peroxidation of mitochrondrial, lyso- 
somal, and plasma membranes [5, 191. 
Under normal conditions, tissues contain 
enough free radical scavengers to protect 
against oxygen free radical damage. Catalase 
protects against tissue injury by the inactiva- 
tion of hydrogen peroxide. Low levels of cat- 
alase activity may play a permissive role in 
ongoing graft rejection. We have been able to 
determine using mixing studies that the de- 
crease in PBCA is not due to the generation 
of a blocking factor in the periphery. One 
possibility may be a decrease in catalase pro- 
duction, although this seems unlikely. An- 
other reason for decreased PBCA may relate 
to increased enzyme catabolism in the re- 
jecting allograft [7]. It would therefore be of 
interest to measure catalase in the allograft. 
In this study, we have demonstrated that a 
decrease in PBCA is a sensitive marker of 
renal allograft rejection, PBCA remains nor- 
mal during episodes of rising creatinine asso- 
ciated with cyclosporine nephotoxicity, sug- 
gesting that PBCA provides a rapid and in- 
expensive discriminant from allograft 
rejection. Although the mechanisms ac- 
counting for these observations are not un- 
derstood, reduced catalase activity may im- 
plicate oxygen free radicals in the early 
pathogenesis of renal allograft rejection. 
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